Homology modeling and atomic level binding study of Leishmania MAPK with inhibitors.
The current therapy for leishmaniasis is not sufficient and it has two severe drawbacks, host-toxicity and drug resistance. The substantial knowledge of parasite biology is not yet translating into novel drugs for leishmaniasis. Based on this observation, a 3D structural model of Leishmania mitogen-activated protein kinase (MAPK) homologue has been developed, for the first time, by homology modeling and molecular dynamics simulation techniques. The model provided clear insight in its structure features, i.e. ATP binding pocket, phosphorylation lip, and common docking site. Sequence-structure homology recognition identified Leishmania CRK3 (LCRK3) as a distant member of the MAPK superfamily. Multiple sequence alignment and 3D structure model provided the putative ATP binding pocket of Leishmania with respect to human ERK2 and LCRK3. This analysis was helpful in identifying the binding sites and molecular function of the Leishmania specific MAPK homologue. Molecular docking study was performed on this 3D structural model, using different classes of competitive ATP inhibitors of LCRK3, to check whether they exhibit affinity and could be identified as Leishmania MAPK specific inhibitors. It is well known that MAP kinases are extracellular signal regulated kinases ERK1 and ERK2, which are components of the Ras-MAPK signal transduction pathway which is complexed with HDAC4 protein, and their inhibition is of significant therapeutic interest in cancer biology. In order to understand the mechanism of action, docking of indirubin class of molecules to the active site of histone deacetylase 4 (HDAC4) protein is performed, and the binding affinity of the protein-ligand interaction was computed. The new structural insights obtained from this study are all consistent with the available experimental data, suggesting that the homology model of the Leishmania MAPK and its ligand interaction modes are reasonable. Further the comparative molecular electrostatic potential and cavity depth analysis of Leishmania MAPK and human ERK2 suggested several important differences in its ATP binding pocket. Such differences could be exploited in the future for designing Leishmania specific MAPK inhibitors.
Awale
Mahendra
M
National Institute of Pharmaceutical Education and Research, Nagar, Punjab, India.
Kumar
Vivek
V
Saravanan
Parameswaran
P
Mohan
C Gopi
CG
D000595:Amino Acid Sequence; D001665:Binding Sites; D006655:Histone Deacetylases / Q000737:chemistry; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology; D007891:Leishmania / Q000201:enzymology*; D008024:Ligands; D008264:Macrophages / Q000187:drug effects / Q000469:parasitology; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D008958:Models, Molecular; D008969:Molecular Sequence Data; D047428:Protein Kinase Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D016415:Sequence Alignment; D055672:Static Electricity; D040681:Structural Homology, Protein; D013816:Thermodynamics; D013997:Time Factors
D007211:Indoles; D008024:Ligands; D047428:Protein Kinase Inhibitors; D020928:Mitogen-Activated Protein Kinases; D006655:Histone Deacetylases; C027185:indirubin